{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089936","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.739630+00:00","generated_at":"2026-05-31T09:05:16.964516+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed","bullets":["Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.","Net loss $4.3M ($0.21 per share) vs $14.0M loss a year ago; operating loss $8.2M vs $11.4M.","Closed up to $50M debt facility with OrbiMed; drew $25M at close; cash $16.5M at June 30.","Warrant exchange completed; 79% of public warrants tendered, simplifying capital structure.","Expects final Phase 1 data for nelitolimod in uveal melanoma and pancreatic cancer in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089936","json":"https://secwatch.observer/filing/0001104659-24-089936.json","markdown":"https://secwatch.observer/filing/0001104659-24-089936.md","text":"https://secwatch.observer/filing/0001104659-24-089936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/0001104659-24-089936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/tm2421775d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:05:16.964516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}